Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

SureCN678896 4-amino-5-chloro-N-[(3S,4R)- 1-[3-(4...

Synonyms: FT-0666150, AC1L3UD2, 102671-04-5

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on Norcisapride

Both linear and nonlinear regression analyses were used to examine the association between the apparent plasma clearance of midazolam and cisapride and the cisapride/norcisapride plasma concentration ratios [1].
The time to reach maximum concentration after drug administration (t(max)) and the apparent elimination half-life (t((1/2)) for cisapride and the pharmacokinetics of norcisapride were not altered [2].
One subject had a doubling in cisapride AUC and C(max) and a decrease in norcisapride/cisapride ratios with red wine and also had the largest interaction with grapefruit juice [2].
Of 10 recombinant human P450s tested, CYP3A4 catalyzed the formation of NORCIS, 3-F-4-OHCIS, and 4-F-2-OHCIS from each enantiomer and racemic cisapride (15 microM) with the highest specific activity (Km values close to those in HLMs) [3].
The kinetics for the formation of NORCIS from (-)-cisapride (Km = 11.9 +/- 4.8 microM; Vmax = 203 +/- 167 pmol/min/mg of protein) or (+)-cisapride (Km = 18.5 +/- 4.7 microM; Vmax = 364 +/- 284 pmol/min/mg of protein) in HLMs exhibited simple Michaelis-Menten kinetics, while a sigmoidal model characterized those of 3-F-4-OHCIS and 4-F-2-OHCIS [3].

Biological context of Norcisapride

Cisapride t((1/2)) and norcisapride pharmacokinetics were not different [2].
Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms [4].

Associations of Norcisapride with other chemical compounds

Plasma concentrations of cisapride and urinary norcisapride were measured by HPLC [5].

Gene context of Norcisapride

The formation rate of each metabolite from each enantiomer (20 microM) in 18 HLMs was highly variable (e.g., NORCIS, >35-fold) and correlated with the activity of CYP3A (r = 0.6-0.85; p < 0.05) [3].
Identification of the human cytochrome P450 (P450) enzymes involved in the metabolism of cisapride and racemic norcisapride [(+/-)-norcisapride] was investigated at 0.1 and 1 microM, concentrations that span the mean plasma C(max) for cisapride [4].

Analytical, diagnostic and therapeutic context of Norcisapride

Norcisapride only could be detected in the dialysate (0.36 +/- 0.067 mg) and was eliminated by a hemodialysis clearance of 34.7 +/- 7.9 ml/min [6].
Cisapride and its metabolite norcisapride were measured by use of HPLC and gas chromatography, respectively [6].
A simple high-performance liquid chromatography assay for the major cisapride metabolite, norcisapride, in human urine [7].

References

Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Lowry, J.A., Kearns, G.L., Abdel-Rahman, S.M., Nafziger, A.N., Khan, I.S., Kashuba, A.D., Schuetz, E.G., Bertino, J.S., van den Anker, J.N., Leeder, J.S. Clin. Pharmacol. Ther. (2003) [Pubmed]
Red wine-cisapride interaction: comparison with grapefruit juice. Offman, E.M., Freeman, D.J., Dresser, G.K., Munoz, C., Bend, J.R., Bailey, D.G. Clin. Pharmacol. Ther. (2001) [Pubmed]
Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. Desta, Z., Soukhova, N., Morocho, A.M., Flockhart, D.A. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Pearce, R.E., Gotschall, R.R., Kearns, G.L., Leeder, J.S. Drug Metab. Dispos. (2001) [Pubmed]
Influence of grapefruit juice on cisapride pharmacokinetics. Gross, A.S., Goh, Y.D., Addison, R.S., Shenfield, G.M. Clin. Pharmacol. Ther. (1999) [Pubmed]
Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. Gladziwa, U., Bares, R., Klotz, U., Dakshinamurty, K.V., Ittel, T.H., Seiler, K.U., Sieberth, H.G. Clin. Pharmacol. Ther. (1991) [Pubmed]
A simple high-performance liquid chromatography assay for the major cisapride metabolite, norcisapride, in human urine. Addison, R.S., Duffy, S.L., Mathers, S.R. Journal of chromatographic science. (1999) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.